Targanta Therapeutics - Top 20 VC deals of 2007

Company: Targanta Therapeutics
Based: Cambridge, MA
Amount: $70M
Round: Third
Investors: Brookside International Incorporated, CDP Capital - Technology Ventures, Canadian Medical Discoveries Fund, Fonds de Solidarite des Travailleurs du Quebec, GeneChem Financial Corporation, Individuals, OrbiMed Advisors, Radius Ventures, Seaflower Ventures, Skyline Ventures, T2C2 Capital, Undisclosed Corporate Investor, VenGrowth Capital Funds

Scoop: Targanta's lead drug candidate is oritavancin for complicated skin and skin structure infections; it’s also in Phase II trials for catheter-related bacteremia and nosocomial pneumonia. The drug developer said that the money would be used to file an NDA for oritavancin, which is anticipated early this year. The company also has a number of antibacterial agents currently in pre-clinical development. Targanta went public in a $57.5 million IPO in May 2007.

More News:
Targanta shares start trading at a discounted price. Report
Targanta raises $70M in third venture round. Report
Targanta files for $86M IPO to push antibiotics. Report

Targanta Therapeutics - Top 20 VC deals of 2007
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.